ClinicalTrials.gg
RecruitingNCT05230784Updated Nov 16, 2026

The PURI-HF (Air Purifiers on Heart Failure) Trial

An interventional study of AirOk Air Purifier and Placebo Air Filter in Heart Failure, sponsored by NYU Langone Health. Recruiting at 3 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 16, 2026Enrollment updatedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Heart Failure by NYU Langone Health — 3 open to participants now, 3 under way, none of them phase 3. Heart Failure · NYU Langone Health.

Planned enrollment
6th of 14
600 · median 113
Started
2024
the only one that year
No phase
8 of 16
3 open now
Registered
10th of 16
by date

Among the 16 studies in Heart Failure by NYU Langone Health, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 10th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

3 of the 16 studies in Heart Failure by NYU Langone Health are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Heart Failure by NYU Langone Health, or all of them as a file.
02

Study summary

Indoor air pollution and fine mode particulate matter with an aerodynamic diameter smaller than 2.5 micrometers (PM2.5) is a major contributor to global morbidity and mortality, particularly due to cardiovascular disease. This project aims to demonstrate the efficacy, feasibility and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India. The findings from the project will add to existing knowledge of innovative and scalable strategies to improve environmental and cardiovascular health worldwide.

The overall objective of this study is to demonstrate the efficacy, feasibility, and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Indoor Air Purifier
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years of age diagnosed with HF with a reduced of ≤ 40% within the last six months in class II-IV.

Exclusion criteria

Exclusion Criteria:

  • listed for a cardiac transplant
  • history of CRT device implantation in last 3 months
  • on oxygen therapy
  • with severe pulmonary disease
  • participants unable to ambulate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    HEPA Air Purifier

    Air purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period.

    Other: AirOk Air Purifier

  • Placebo comparator
    EGAPA Air Purifier

    Air purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period.

    Other: Placebo Air Filter

Interventions

  • OtherAirOk Air Purifier

    The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.

  • OtherPlacebo Air Filter

    Participants in the placebo arm will receive an air purifier with only the EGAPA filter.

06

What researchers measure

Primary outcomes

  1. Change in Distance Walked

    The distance in meters will be recorded during a 6-minute walk test (MWT)

    Time frame: Baseline, 4 months, 8 months, 12 months

Secondary outcomes

  1. Change in Systolic Blood Pressure (SBP)

    Time frame: Baseline, 4 months, 8 months, 12 months

  2. Change in Diastolic Blood Pressure (DBP)

    Time frame: Baseline, 4 months, 8 months, 12 months

  3. Change in Heart Rate

    Time frame: Baseline, 4 months, 8 months, 12 months

  4. Change in pro B-type natriuretic peptide (Pro-BNP) Levels

    Time frame: Baseline, 4 months, 8 months, 12 months

  5. Change in Number of Hospitalizations

    Time frame: Baseline, 4 months, 8 months, 12 months

07

Study locations

3 of 3 sites recruiting
  • Centre for Chronic Disease Control (CCDC)
    Thiruvananthapuram, Kerala, India
    Recruiting
  • All India Institute of Medical Sciences (AIIMS)
    Delhi, Punjab, India
    Recruiting
  • Public Health Foundation of India (PHFI)
    Ludhiana, Punjab, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will have access upon reasonable request. Requests should be directed to rajesh.vedanthan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2028, 47 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 47 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2022
First posted
Feb 9, 2022
StartActual
Mar 6, 2024
Primary completionEst.
Feb 29, 2028
CompletionEst.
Apr 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
255→600
Nov 16, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameChange in Distance WalkedBaseline, 12 months → Baseline, 4 months, 8 months, 12 months
Nov 16, 2026
Secondary outcomes
5 time frame changed
What changed in the outcomes
  • Time frameChange in Systolic Blood Pressure (SBP)Baseline, 12 months → Baseline, 4 months, 8 months, 12 months
  • Time frameChange in Diastolic Blood Pressure (DBP)Baseline, 12 months → Baseline, 4 months, 8 months, 12 months
  • Time frameChange in Heart RateBaseline, 12 months → Baseline, 4 months, 8 months, 12 months
  • Time frameChange in pro B-type natriuretic peptide (Pro-BNP) LevelsBaseline, 12 months → Baseline, 4 months, 8 months, 12 months
  • Time frameChange in Number of HospitalizationsBaseline, 12 months → Baseline, 4 months, 8 months, 12 months
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Enrollment 255→600
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameChange in Distance WalkedBaseline, 12 months → Baseline, 4 months, 8 months, 12 months
    Secondary outcomes 5 time frame changed
    What changed in the outcomes
    • Time frameChange in Systolic Blood Pressure (SBP)Baseline, 12 months → Baseline, 4 months, 8 months, 12 months
    • Time frameChange in Diastolic Blood Pressure (DBP)Baseline, 12 months → Baseline, 4 months, 8 months, 12 months
    • Time frameChange in Heart RateBaseline, 12 months → Baseline, 4 months, 8 months, 12 months
    • Time frameChange in pro B-type natriuretic peptide (Pro-BNP) LevelsBaseline, 12 months → Baseline, 4 months, 8 months, 12 months
    • Time frameChange in Number of HospitalizationsBaseline, 12 months → Baseline, 4 months, 8 months, 12 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05230784
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
Mar 6, 2024
Primary completion
Feb 29, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Rajesh Vedanthan, MD, MPH
Contact
Rajesh.vedanthan@nyulangone.org
646-501-3890
Jessica Gjonaj
Contact
Jessica.gjonaj@nyulangone.org
646-501-3663
Rajesh Vedanthan, MD, MPH
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion